ClinicalTrials.gg
Not yet recruitingNCT07425600INDOFIBUpdated Apr 22, 2026

Individualized Dose of Fibrinogen Following Cardiopulmonary Bypass

An observational study in Fibrinogen Deficiency in Complex Cardiac Surgery, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Not yet recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Study summary

Heart surgery is essential for many cardiovascular conditions, but it is a major operation with a significant mortality rate of around 4% in Europe. Among the main complications encountered postoperatively, hemorrhage occurs at a rate of around 8.2% for severe bleeding and 1.6% for massive bleeding.

Hemorrhagic complications are caused by hemostasis disorders attributable to extracorporeal circulation (ECC). Despite recent advances in material design, ECG activates hemostasis, leading to the consumption of various coagulation factors, including fibrinogen, as well as the absorption of fibrinogen by the various components of the circuit. Postoperative hypofibrinogenemia has multiple causes and is correlated with the risk of bleeding and the need for red blood cell transfusions in cardiac surgery under CPB, and therefore indirectly with mortality related to this procedure. The administration of fibrinogen concentrates is the standard treatment; however, the optimal dose to normalize fibrinogen levels and reduce bleeding is unknown.

Good practice recommendations in cardiac surgery suggest administering fibrinogen in cases of bleeding associated with fibrinogen levels below 2 g/L. However, the time required to obtain fibrinogen level results from the laboratory (approximately 1 hour) is not always compatible with the urgency of transfusion needs in these situations. Transfusion optimization strategies have been proposed using viscoelastic tests (ROTEM, Werfen, or Quantra, Stago, for example). The administration of fibrinogen guided by these tests has reduced the need for red blood cell transfusions; however, this strategy increases the cost attributable to fibrinogen because it favors its administration without individualizing the dose to be administered. To date, it is not possible to individualize the dose of fibrinogen to be administered based on baseline fibrinogen levels and kinetics. Developing such an administration strategy would allow for i) faster correction of hypofibrinogenemia and ii) a reduction in associated costs by administering the minimum effective dose.

02

Conditions studied

  • Fibrinogen Deficiency in Complex Cardiac Surgery

Browse trials for

Keywords

  • fibrinogen
  • cardiopulmonary bypass
  • pharmacokinetic modeling
03

In context

Afibrinogenemia

32 studies on the registry are indexed under Afibrinogenemia; 5 are open to participants now.

This study's planned enrollment of 150 is close to the median of 150 across 11 observational studies indexed under Afibrinogenemia.

Browse Afibrinogenemia studies →

Lead sponsor

Centre Hospitalier Universitaire de Saint Etienne is the lead sponsor of 598 studies on the registry; 128 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient admitted for cardiac surgery and receiving fibrinogen administration after weaning from cardiopulmonary bypass

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult
  • Patient undergoing cardiac surgery under cardiopulmonary bypass
  • Indication for fibrinogen administration after cardiopulmonary bypass weaning
  • Patient affiliated with or entitled to social security coverage
  • Patient who has received about the study

Exclusion criteria

Exclusion Criteria:

  • Administration of fibrinogen in the context of massive transfusion
  • to the administration of the fibrinogen concentrate under study
  • Constitutional afibrinogenemia, constitutional dysfibrinogenemia, or any other constitutional diseases related to hemostasis
  • Pregnant women, women in labor, breastfeeding women
  • Adults subject to legal protection measures (guardianship or curatorship)
  • Patients with preoperative anemia \< 6 g/dL
  • Patients with a \< 24 hours
  • Patients who do not speak French
  • Refusal to participate
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patient receiving fibrinogen administration after weaning from cardiopulmonary bypass

    Biological: Blood samples for PK

Interventions

  • BiologicalBlood samples for PK

    Samples will be taken at regular intervals to characterize the kinetics of fibrinogen evolution post-transfusion. Sampling times will be at t = 0 (before transfusion), 10 minutes, H1, H3, H6, H9, H12, D1, and D2 relative to the start of fibrinogen transfusion (measurement of fibrinogen levels and viscoelastic tests), then every two days until the end of hospitalization (measurement of fibrinogen levels only).

06

What researchers measure

Primary outcomes

  1. Characterize the sources of variability in plasma fibrinogen levels in response to administration of fibrinogen concentrate after cardiac surgery with cardiopulmonary bypass.

    Measurement of blood samples using the Clauss technique

    Time frame: During surgery (day 0) (before transfusion then at 10min, 1 hour, 3 hours, 6 hours, 9 hours, 12 hours after transfusion) then at day 1, day 2, day 4 and day 6.

Secondary outcomes

  1. Characterize the sources of variability in response to fibrinogen concentrate administration as assessed by the ROTEM viscoelastic test.

    Measurement of blood samples using the ROTEM viscoelastic test

    Time frame: During surgery (day 0) (before transfusion then at 10min, 1 hour, 3 hours, 6 hours, 9 hours, 12 hours after transfusion) then at day 1 and day 2.

  2. Characterize the sources of variability in response to fibrinogen concentrate administration as assessed by the Quantra viscoelastic test.

    measurement of blood samples using the Quantra viscoelastic test

    Time frame: During surgery (day 0) (before transfusion then at 10min, 1 hour, 3 hours, 6 hours, 9 hours, 12 hours after transfusion) then at day 1 and day 2.

  3. Characterize the correlation between fibrinogen exposure and postoperative bleeding after fibrinogen administration.

    Blood loss in ml measured via surgical drains

    Time frame: During surgery (day 0) then at day 1 and day 2.

  4. Study the relationship between different estimators of fibrinogen concentration.

    Correlation coefficient between the different estimators of fibrinogen concentration and description using a Bland-Altman plot.

    Time frame: through study completion, an average of 7 days

07

Study locations

2 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Oct 2028, 23 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2026
First posted
Feb 23, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Oct 31, 2028
CompletionEst.
Nov 7, 2028
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07425600
Collaborators
Laboratoires LFB
Responsible party
Sponsor
First posted
Feb 23, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Oct 31, 2028 (estimated)
Completion
Nov 7, 2028 (estimated)
Last update
Apr 22, 2026

Study contacts

Julien LANOISELEE, MD
Contact
julien.lanoiselee@chu-st-etienne.fr
(0)477120388 ext. +33
Julien LANOISELEE, MD
principal investigator · CHU de Saint-Etienne

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion